| pubmed-article:8255845 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8255845 | lifeskim:mentions | umls-concept:C0004561 | lld:lifeskim |
| pubmed-article:8255845 | lifeskim:mentions | umls-concept:C0028833 | lld:lifeskim |
| pubmed-article:8255845 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8255845 | lifeskim:mentions | umls-concept:C1257963 | lld:lifeskim |
| pubmed-article:8255845 | lifeskim:mentions | umls-concept:C0175630 | lld:lifeskim |
| pubmed-article:8255845 | lifeskim:mentions | umls-concept:C1514468 | lld:lifeskim |
| pubmed-article:8255845 | pubmed:issue | 815 | lld:pubmed |
| pubmed-article:8255845 | pubmed:dateCreated | 1994-1-12 | lld:pubmed |
| pubmed-article:8255845 | pubmed:abstractText | The role of somatostatin analogues in the medical management of insulinomas is unclear. We describe an elderly patient with clinical and biochemical features of endogenous hyperinsulinism attributable to a benign islet B cell disorder whose incapacitating neuroglycopaenic symptoms responded dramatically to octreotide 50 micrograms subcutaneously at 2200 h each night. Octreotide suppressed inappropriate plasma concentrations of insulin thereby preventing fasting hypoglycaemia. Fasting concentrations of proinsulin, and 32-33 split proinsulin, as determined by two-site monoclonal antibody-based immunoradiometric assays, were also suppressed by octreotide. | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8255845 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8255845 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8255845 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8255845 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8255845 | pubmed:issn | 0032-5473 | lld:pubmed |
| pubmed-article:8255845 | pubmed:author | pubmed-author:NattrassMM | lld:pubmed |
| pubmed-article:8255845 | pubmed:author | pubmed-author:ClarkP MPM | lld:pubmed |
| pubmed-article:8255845 | pubmed:author | pubmed-author:SomervilleWW | lld:pubmed |
| pubmed-article:8255845 | pubmed:author | pubmed-author:PaceJJ | lld:pubmed |
| pubmed-article:8255845 | pubmed:author | pubmed-author:KrentzA JAJ | lld:pubmed |
| pubmed-article:8255845 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8255845 | pubmed:volume | 69 | lld:pubmed |
| pubmed-article:8255845 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8255845 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8255845 | pubmed:pagination | 735-8 | lld:pubmed |
| pubmed-article:8255845 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:meshHeading | pubmed-meshheading:8255845-... | lld:pubmed |
| pubmed-article:8255845 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8255845 | pubmed:articleTitle | Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism. | lld:pubmed |
| pubmed-article:8255845 | pubmed:affiliation | Diabetic Clinic, General Hospital, Birmingham, UK. | lld:pubmed |
| pubmed-article:8255845 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8255845 | pubmed:publicationType | Case Reports | lld:pubmed |
